CLYM — Climb Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1768446 ·
Last close
$10.86
Market Cap
$623.76M
52W High
$18.33
52W Low
$1.63
ADV30
1,627,905
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -15,359,000 | -13,498,000 | 246,294,000 | 44,107,000 | 6,747,000 |
| Mar 2026 | 0 | — | -15,211,000 | -13,722,000 | 152,372,000 | 8,356,000 | 4,287,000 |
| Dec 2025 | 0 | — | -19,296,000 | -17,516,000 | 167,744,000 | 35,685,000 | 7,269,000 |
| Sep 2025 | 0 | — | -14,892,000 | -12,888,000 | 182,304,000 | 25,803,000 | 5,301,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-52,699,000
Investing CF
$-29,420,000
Financing CF
$103,687,000
CapEx
$-109,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.83
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-316,947,000
Inventory
—
Receivables
$1,366,000
ST Investments
$139,016,000
EBIT TTM
$-64,758,000
Pretax Income TTM
$-57,624,000
Interest Exp TTM
—
Analysts
14
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -67,883,000 | -59,851,000 | 167,744,000 | 7,269,000 | 160,475,000 | -54,356,000 |
| Dec 2024 | 0 | -30,361,000 | -73,897,000 | 217,187,000 | 5,306,000 | 211,881,000 | -15,562,000 |
| Dec 2023 | 0 | -40,275,000 | -35,119,000 | 110,469,000 | 2,870,000 | 107,599,000 | -20,599,000 |
| Dec 2022 | 0 | -45,135,000 | -45,244,000 | 134,992,000 | 6,277,000 | 128,715,000 | -37,369,000 |
TTM Snapshot
Revenues TTM
$9,837,000
NetIncome TTM
$-52,792,000
OpCashFlow TTM
—
Assets (Latest)
$152,372,000
Forward EPS
$-1.00
Max Pain — expiry 2026-10-16
max pain strike: $12.50 · spot: $11.12 · call oi: 1,719 · put oi: 2,745
Expected Move to 2026-10-16:
±$1.42
(12.81%) —
implied range
$9.69 –
$12.54
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IRWD | IRONWOOD PHARMACEUTICALS INC | $639.48M | $3.87 | — |
| AQST | Aquestive Therapeutics, Inc. | $597.44M | $4.76 | — |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $653.22M | $11.00 | — |
| NVCT | Nuvectis Pharma, Inc. | $657.13M | $20.13 | — |
| SLN | Silence Therapeutics plc | $591.71M | $9.52 | — |
News headlines (Yahoo Finance, 1h cache)
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
2026-10-02 13:30 · Yahoo
Why Climb Bio, Up 1,300% Over 17 Months, Just Took A Tumble
2026-09-03 20:51 · Yahoo
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
2026-09-03 18:02 · Yahoo
Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data
2026-09-03 13:37 · Yahoo
Climb Bio to Present at Upcoming Investor Conferences
2026-09-02 11:00 · Yahoo
Do Climb Bio’s (CLYM) Mixed Loss Trends Reveal a Shifting Path to Sustainable Scale?
2026-08-18 07:09 · Yahoo
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-06 11:00 · Yahoo
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
2026-06-11 11:00 · Yahoo
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
2026-06-05 11:00 · Yahoo
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
2026-05-26 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.